En Español
The prescription drug Xarelto is a blood thinner designed to help people who have suffered a stroke or have other symptoms of blood clotting. However, in some patients, it may cause excessive bleeding. In some other blood thinners, the excessive bleeding can be stopped by administering Vitamin K. In the case of Xarelto, there is no approved agent to approve the bleeding. Business Insider reports that one case has been scheduled to move forward in a class action lawsuit facing the makers of the drug.
This is the first case to go forward in the Philadelphia Court of Common Pleas, where more than 1,500 cases are currently centralized in a mass tort program. The lawsuit was filed on behalf of an Indiana woman who suffered from massive intestinal bleeding after taking the drug.
The attorneys for the plaintiff claim that Johnson & Johnson manipulated clinical trial data and downplayed important information that made Xarelto seem safer and more effective than other blood thinners like warfarin.
Xarelto received FDA approval in 2011. Johnson & Johnson’s most recent earnings statement indicates that the company is facing more than 21,000 lawsuits filed throughout the United States. Plaintiffs have noted the lack of a reversal agent, a one-size-fits-all dosing regimen, and the claim that regular monitoring tests were unnecessary.
The majority of the lawsuits are pending in the U.S. District Court, Eastern District of Louisiana. Three trials have already concluded with defense verdicts. However, additional claims have been filed in Delaware, California, and Mississippi.
Have you been injured by the prescription drug Xarelto? You may be entitled to compensation. Let the attorneys at the offices of John Foy & Associates fight to help you. Call us today.
